Approval · Notice of Compliance 32704 · 2024
JAMP SUMATRIPTAN DF: Notice of Compliance 32704
Issued February 14, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32704
- Date
- February 14, 2024
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- IMITREX DF (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP SUMATRIPTAN DF | 02545292 | Marketed |
| JAMP SUMATRIPTAN DF | 02545306 | Marketed |
| JAMP SUMATRIPTAN DF | 02545314 | Marketed |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB